Approximately 10% of patients with asthma have persisting symptoms and exacerbations despite combination therapy with long-acting b agonists and inhaled corticosteroids. 1 This inadequate therapeutic response may be due to medication-refractory asthma or difficult-to-manage asthma arising from confounding issues such as poor inhaler technique, poor adherence, or coexisting comorbid disease. [1] [2] [3] Adherence to medication may be compounded by the fact that some patients may demonstrate a reasonable inhaler technique when directly observed, but may be careless in their inhaler use on a day-to-day basis. [4] [5] [6] Comorbidities and complicating conditions such as rhinosinusitis, gastroesophageal reflux (GER), and obesity also play significant roles in uncontrolled asthma. 1 Several risk factors have been identified with a more severe asthma phenotype. These include women, obesity, and tobacco exposure, some of which are risks factors for GER. 7 Previous studies suggest that GER, although often asymptomatic, is common in the asthmatic population, 8 but it is unclear whether any association between GER and asthma severity is the result of confounding or because of a direct independent effect. Trials examining the potential therapeutic use of proton pump inhibitors (PPIs) in asthma have had mixed results [9] [10] [11] ; therefore, current evidence does not support their routine use to improve clinical outcomes in asthma. However, although GER may predispose to aspiration, it is not synonymous with it. In addition, treatment with PPIs reduces gastric acidity and thus acidity of reflux, but does not prevent nonacid reflux or aspiration into the airways of at risk patients. 12 If such nonacid reflux is mechanistically important, then PPIs would be expected to be of limited efficacy.
Pepsin is produced in the stomach in response to substances such as cholecystokinin (CCK), gastrin, vasoactive intestinal peptide (VIP), secretin, and insulin. Levels of pepsin, used as a biomarker of gastric aspiration, are elevated in BAL of lung transplant recipients, and are associated with acute and chronic rejection. 13 Fundoplication, which reduces or prevents aspiration, has been successfully used after lung transplant in uncontrolled studies. Successful fundoplication has also been reported in patients with asthma, albeit in case reports and series. 14 The aim of this study was to determine the prevalence of aspiration (as defined by detectable pepsin in BAL) in a cohort of patients with mild, moderate, and severe asthma. The association of BAL differential, smoking status, steroid use (oral as well as inhaled), PPI use, BMI, and the presence of atopy with pepsin level was also examined.
Methods
Study approval was granted by the University College Cork's clinical research ethics committee (ECM 4 (m) 01/10/13). After informed consent was received, 78 people with asthma were prospectively recruited from an asthma clinic in Cork University Hospital. On the morning of bronchoscopy, spirometry and the validated Asthma Control Questionnaire 7 (ACQ-7) were completed by enrolled subjects. 15 A history of exacerbations over the preceding 12-month period was ascertained and validated against both inpatient and community pharmacy prescriptions. Patients had blood drawn for peripheral eosinophil count, IgE, and radioallergosorbent testing for grass pollen, animal danders, house dust mite, and Aspergillus. Finally, testing of fractional exhaled nitric oxide was performed using the NIOX MINO device (Aerocrine AB). 16 
Bronchoscopy and BAL
Bronchoscopy was performed under conscious sedation with patients in a semireclined position.
BAL was obtained from the right middle lobe or lingula as a standardized 3 Â 60 mL procedure. BAL pH was measured using nonbleeding pH indicator strips immediately postbronchoscopy (Merck). The BAL sample was divided, and clinical microbiology was assessed in a standardized fashion. Differential cell counts were made on Kwik Diff stain (Thermo Scientific) cytocentrifuge preparations. Cell-free BAL supernatants were prepared by centrifugation (10 minutes, 500g, 21 C); aliquots were subsequently stored at À80 C before enzymelinked immunosorbent assay (ELISA) testing.
Pepsin ELISA
A locally developed indirect ELISA was used to measure pepsin. 17 Briefly, 100 mL of pepsin standard (pepsin from porcine gastric mucosa, Sigma) and undiluted BAL supernatants were allowed to adsorb onto a 96-well plate (Nunc MaxiSorp) in triplicate. Nonspecific binding sites were blocked with 1% ELISA grade bovine serum albumin (Merck Millipore) in phosphate-buffered saline (pH 7.4). The primary antibody was specific to porcine pepsin (Biodesign International, Catalog No. W59117G). Secondary antibody was horseradish peroxidase-conjugated rabbit, anti-goat (Sigma). Antibodies were diluted in Trisbuffered saline (20 mM Triza base, 150 mM NaCl, pH 7.4) containing 0.1% bovine serum albumin and 0.05% Tween 20. The substrate used was 2,2 0 -Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) and the reaction was stopped with an equal volume of 1% sodium dodecyl sulfate. Negative controls were performed with the omission of primary antibody.
Barium Swallow
A standard double-contrast barium swallow study was carried out with patients in both upright and supine positions. Where spontaneous GER was not demonstrated, provocation maneuvers were used, starting with a cough, followed by Valsalva manoeuvres, rolling the patient, and the water siphon test. Secondary signs of reflux were recorded, including esophageal reflux, cricopharyngeal bars, and hiatal herniae, but only patients in whom reflux was demonstrated during the procedure were characterized as positive for GER.
Statistics
The distribution, central tendency, and spread of each variable were examined using standard tabular and graphical methods. In primary analysis, the association of aspiration with markers of disease severity was examined in univariate analysis using Fisher exact test and in multivariate analysis using logistic regression. Analysis was conducted using GraphPad Prism 6.
Results
Patient characteristics are described in Table 1 . Seventyeight patients were recruited (49 women). There were 8 current (14.8 pack-years), 19 ex-smokers (15 packyears), and 51 nonsmokers. There were no significant differences in smoking status across disease severity.
Thirty-two patients demonstrated positive barium studies. Twenty-six patients were on PPIs and/or H 2 -antagonist therapy. Eight patients were on maintenance regimens of oral steroids at the time of testing (range, 5-20 mg daily). In total, 63 patients underwent all investigations, with a further 15 patients undergoing all investigations except barium swallow. Fig 1) . 19 A significant correlation was seen between peripheral and BAL eosinophils, r ¼ 0.39 (P < .0005).
There was no association between detectable pepsin and disease severity, asthma control, exacerbation frequency or FEV 1 ( Fig 1A) . Similar results were found when the model was further adjusted for smoking history, BMI, PPI use (Fig 1B) , eosinophil and neutrophil counts, and serum IgE. BAL pH also had no significant association with disease severity (Fig 1C) .
There was no significant difference between barium study result and BAL pepsin; mean (SD) pepsin for positive study 3.4 (1.3) vs 3.8 (1.4) ng/mL for negative study, P ¼ nonsignificance (Fig 1D) . When the cohort was divided into positive/negative barium swallow, there was no association between positive barium swallow and ACQ-7, asthma severity, exacerbation frequency, or FEV 1 on either univariate or multivariate analyses.
In a simultaneous multivariable linear regression model, ACQ-7 scores were significantly related to oral corticosteroid use
Discussion
Research to date pertaining to the possible utility of BAL pepsin as a marker of aspiration has been undertaken mainly in the areas of acute lung injury, end-stage lung disease, and post-lung transplantation. 13, 17, 20 It has been shown that detection of pepsin and bile acids in BAL and exhaled breath condensate can be used to aid identification of lung transplantation recipients with GER-induced aspiration. Elevated levels are associated with acute allograft rejection and/or bronchiolitis obliterans syndrome. 17 The use of pepsin as a surrogate for aspiration and therefore increased risk of rejection has led to its use as a means for justifying antireflux surgery in this niche population, with clinical outcomes suggesting a protective role in terms of nonallogenic injury. 21 It has long been postulated that there is a link between GER and asthma severity. 7 Despite this, there has been a paucity of research specifically looking at airway pepsin as a biomarker of adverse clinical outcome and disease severity in the asthmatic lung. Results of this study demonstrated a median pepsin concentration of 3.58 ng/mL (range, 2.53-15.78 ng/mL), in the 58.9% of patients demonstrating detectable pepsin, confirming that aspiration does occur in patients with asthma. Despite its demonstrable presence, pepsin concentration showed no significant association with clinical markers of disease severity or asthma control.
Asthma and GER are known to share potential risk factors, such as smoking and obesity. BAL pepsin levels demonstrated no association with either BMI or smoking history. More important, there was no significant difference in pepsin levels when divided according to the presence or absence of GER by barium swallow.
The median pepsin concentration of 3.58 ng/mL, when compared with findings in other studies (using similar BAL sampling techniques), was significantly greater than control groups (median, 1.1 ng/mL), and patients with chronic cough (median, 0 ng/mL). This was consistent with the presence of microaspiration into the lungs of some people with asthma. 17 The levels are below those seen after lung transplantation (median, 8.3 ng/mL), which is not surprising because lung allograft recipients are regarded as being especially vulnerable to aspiration because of gastroparesis, impaired cough, 22 and dysfunctional mucociliary clearance. 23 Pepsin levels, however, did not exhibit a significant correlation with asthma exacerbation frequency (P ¼ .66). When patients were subdivided into groups by exacerbation frequency (# 3, 4-6, and $ 7 exacerbations/y), there was no significant difference in pepsin concentration across the groups (3.27, 2.53, and 3.51 ng/mL, respectively). There remains the possibility that low-grade exposure to aspiration over a prolonged period may still play a role in promoting airway inflammation and increase the risk of future exacerbation, but the study does not suggest that this is associated with poorer asthma control.
Pepsin levels were not significantly different in patients treated with maintenance acid suppression therapy (median, 2.85 ng/mL) compared with patients who were untreated (median, 2.79 ng/mL; P ¼ NS). This provides evidence of gastric aspiration even in patients who were treated with maintenance PPIs. Similar results have been previously reported in the posttransplant population. 15 This may partially explain why trials examining the potential use of PPIs in asthma have afforded mixed results. [9] [10] [11] 20 In this study, we used pepsin and barium swallow (with provocation), rather than pH manometry/ 24-hour impedance to assess reflux. Barium swallow (esophagography) maintains a role in the modern assessment of GER, especially in patients with symptoms severe enough to warrant the consideration of surgical intervention. [24] [25] [26] [27] [28] Despite its many limitations, a recent consensus statement from the Society of Abdominal Radiology has recommended that, because of its inexpensive and noninvasive nature, in conjunction with its wide availability, that barium swallow should be considered as a first-line test for the investigation of GER. 29 Although the sensitivity of the standard barium swallow for the detection of reflux is often quoted as low as 35% to 50%, 30 with the addition of provocative maneuvers, the sensitivity of barium swallow approaches that of pH testing. 31, 32 Because of an interest in the role of aspiration (be it acidic or nonacidic refluxate) barium swallow (at the time of initial study planning and approval) was believed to be an appropriate means to assess for reflux with the presence of BAL pepsin ultimately defining the presence of aspiration. The results demonstrated, however, no significant relationship between barium journal.publications.chestnet.org swallow and either pepsin concentration or exacerbation frequency, thereby suggesting that barium swallow did not accurately reflect the presence of aspiration in this cohort. Although we did not assess for nocturnal reflux symptoms, across the entire asthma disease severity, there was no observable relationship to the presence of aspiration or the treatment effect of PPI. Furthermore, the study would undoubtedly have been strengthened by performing pH manometry/24-hour impedance in these patients and exploring whether this test reflects BAL pepsin levels.
Further studies have looked at the effect of PPIs on acidic bile salts as opposed to pepsin. Hou et al 33 demonstrated
in an epithelial cell model that omeprazole inhibits IL-8 secretion stimulated by exposure to acid and bile salts. They demonstrated that acidic bile salts activate the IL-8 promoter through nuclear factor-KB and activator protein 1 DNA binding sites, and that omeprazole inhibits IL-8 production by blocking nuclear translocation of p65, as well as decreased binding of p65, c-jun, and c-fos to the IL-8 promoter. These effects occurred independently of the effects on gastric acid secretion, demonstrating a novel mechanism that might contribute to the beneficial effects of PPIs in the treatment of reflux-related pulmonary inflammation. The caveat to this finding comes from research published by Pauwels et al, 34 in which they examined the effect of gastric aspirates from patients with cystic fibrosis (CF) being treated with a PPI and found that such aspirates demonstrated an enhanced inflammatory effect (higher IL-8 production) on CF bronchial epithelial cells. It has recently been shown that microbiological growth from gastric juice occurred when gastric juice pH was > 4 and that gastric and airway microbiomes of people with CF who reflux are similar, indicating a possible mechanism to explain such observations. 35, 36 Because chronic PPI treatment in CF may result in a paradoxically proinflammatory effect in airways, alternative antireflux therapies may need to be considered.
The study has several possible limitations. Having only 17% of the patients designated as Global Initiative for Asthma 5, limits the strengths of the conclusions. Furthermore, we did not assess another commonly cited asthma outcome measure: bronchial hyperreactivity. This would undoubtedly have been of interest, and would have enhanced the findings.
There also exists a plausible alternative mechanism for reflux-mediated exacerbation of asthma in the form of vagally mediated, reflexive bronchospasm. Acidic however, there does not seem to be a clear link between its presence and disease severity. It may be that in people with asthma, pepsin in itself is not an accurate biomarker of the inflammatory airway process that results from exposure to chronic aspiration. Alternatively, it may be that chronic exposure over time to low levels of aspirate is sufficient to drive an inflammatory response causing subsequent differences in clinical severity. Further studies at cellular level are needed to examine the underlying pathways involved and ascertain whether the presence of pepsin is indeed a marker of a pro-inflammatory state. However, because of the lack of clearly demonstrable difference between pepsin levels in patients with differing asthma severity, it may ultimately be that the effect of aspiration on disease severity at a clinical level has been overstated.
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